The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells

Castration-resistant prostate cancer (CRPC) ultimately occurs after a period of treatment with androgen deprivation therapy. Furthermore, CRPC patients can only derive limited survival benefits from traditional cytotoxic drugs. HSP90, which is a molecular chaperone, plays a vital role in client prot...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Cancer Res
Autors principals: Peng, Ruixian, Li, Zhenyu, Lin, Zhiyuan, Wang, Yang, Wang, Wei, Hu, Bo, Wang, Xilong, Zhang, Jun, Wang, Yangyun, Zhou, Renyuan, Lu, Chunhua, Shen, Yuemao, Wang, Jifeng, Shi, Guowei
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4656741/
https://ncbi.nlm.nih.gov/pubmed/26693070
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars